Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.54+3.8%$7.58$6.13▼$17.43$645.66M1.461.37 million shs1.44 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+3.77%+1.43%+10.48%+32.20%-31.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.54+3.8%$7.58$6.13▼$17.43$645.66M1.461.37 million shs1.44 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+3.77%+1.43%+10.48%+32.20%-31.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.75Moderate Buy$15.0075.64% UpsideCurrent Analyst Ratings BreakdownLatest CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)4/28/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.004/28/2026CRMDCorMedix Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$19.004/28/2026CRMDCorMedix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.004/27/2026CRMDCorMedix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.004/27/2026CRMDCorMedix D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/6/2026CRMDCorMedix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.003/5/2026CRMDCorMedix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $14.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$311.71M2.15$2.12 per share4.02$5.14 per share1.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix$163.05M$2.134.0147.44N/A45.25%45.57%24.76%8/6/2026 (Estimated)Latest CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million3/5/2026Q4 2025CRMDCorMedix$0.86$0.16-$0.70$0.16$127.02 million$128.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedix0.332.972.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3078.45 million75.71 millionOptionableCRMD HeadlinesRecent News About These CompaniesCorMedix Inc (NASDAQ:CRMD) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 31, 2026 | americanbankingnews.comCorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long RunMay 27, 2026 | seekingalpha.comCorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift LoomsMay 22, 2026 | marketbeat.comUBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMDMay 19, 2026 | marketbeat.comCorMedix: Long-Term Prospects Remain Poor Despite Q1 BeatMay 18, 2026 | seekingalpha.comDoes Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?May 18, 2026 | finance.yahoo.comHC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD)May 18, 2026 | marketbeat.comA Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year GuidanceMay 16, 2026 | finance.yahoo.comCorMedix Inc $CRMD Shares Bought by Vanguard Group Inc.May 16, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Cormedix (CRMD)May 15, 2026 | theglobeandmail.comCRMD Q1 Earnings Beat on DefenCath Momentum, Guidance RaisedMay 15, 2026 | zacks.comCorMedix Inc. (NASDAQ:CRMD) Q1 2026 Earnings Call TranscriptMay 15, 2026 | insidermonkey.comCormedix Therapeutics to Participate in two Upcoming Investor ConferencesMay 15, 2026 | globenewswire.comCormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 15, 2026 | finance.yahoo.comCRMD stock soared 18% today – here’s what fueled CorMedix’s triple-digit Q1 revenue surgeMay 14, 2026 | msn.comCorMedix (CRMD) Q1 2026 Earnings TranscriptMay 14, 2026 | finance.yahoo.comCorMedix (NASDAQ:CRMD) Issues Earnings ResultsMay 14, 2026 | marketbeat.comCorMedix Inc. (CRMD) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comCorMedix: Q1 Earnings SnapshotMay 14, 2026 | wtop.comWCorMedix shares jump after revenue beat and higher full-year guidanceMay 14, 2026 | msn.comCorMedix Q1 Earnings Call HighlightsMay 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRMD Company DescriptionsCorMedix NASDAQ:CRMD$8.54 +0.31 (+3.77%) Closing price 06/4/2026 04:00 PM EasternExtended Trading$8.59 +0.05 (+0.59%) As of 06/4/2026 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
